# Perseus

> Perseus is a VC fund in Washington backing Biotechnology and Medical. See 16 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Washington, United States
- Total investments: 16
- Last investment: Nov 2012
- Lead investor: 44%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/perseus-llc/about/
- Website: http://www.perseusllc.com

Perseus is a merchant bank and private equity fund management company.

## Contacts

5 contacts available for Perseus. Shizune tracks 8 team members at Perseus. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/perseus?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 25% |
| Medical | 3 | 19% |
| Health Care | 3 | 19% |
| Energy | 2 | 13% |
| Internet | 2 | 13% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 19% |
| Series C | 3 | 19% |
| Funding Round | 2 | 13% |
| Series A | 1 | 6% |
| Series D | 1 | 6% |

8 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Kenneth M. Socha | Senior Managing Director | 0 | — |
| Alexandra Gardiner | Vice President | 0 | — |
| Joanne Marshall Shea | Vice President | 0 | — |
| John C. Fox | Senior Managing Director | 0 | — |
| John Schwieters | Senior Executive | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BlueWillow Biologics | BlueWillow Biologics operates as a clinical-stage privately-held biopharmaceutical company. It focuses on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform. Its platform employs novel oil-in-water nano-droplets for products administered to the skin andnose.The company was founded as a spin-off from the University of Michigan and is headquartered in Ann Arbor, Michigan. | $11M | Series C | Nov 28, 2012 |  |
| CeNeRx BioPharma | CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for thetreatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina. | $13M | Series C | Aug 13, 2010 |  |
| Metamark Genetics | Metamark Genetics, Inc is a life science company dedicated to the development of prognostic and predictive diagnostic tests that will enable personalized treatment planning for cancer patients, improved outcomes, and reduced healthcare costs.Metamark was founded in November, 2007 to transform cancer diagnosis and treatment by developingpioneering diagnostic products based on its Prognosis Determinantsâ„¢ Platform. Prognosis Determinantsâ„¢ are functionally validated genetic elements at the core of cancer progression across many major cancer types. Based on pioneering research in melanoma by Dr. Lynda Chin at the Dana-Farber Cancer Institute and Harvard Medical School, the Prognosis Determinantsâ„¢ were first discovered as functionally active drivers of metastasis that confer poor outcome. Prognosis Determinantsâ„¢ have been shown to be relevant to a broad spectrum of different tumors and can stratify patients according to their overall and metastasis-free survival. |  | Series B | Aug 13, 2010 |  |
| Lumexis | Lumexis Corporation engages in developing, manufacturing, and marketing fiber-to-the-screen (FTTS) in-flight entertainment (IFE) and communication systems. The company also provides customer support, training, and software services. Lumexis Corporation was founded in 2003 and is based in Costa Mesa, California. | $15M |  | Nov 30, 2009 |  |
| BlueWillow Biologics | BlueWillow Biologics operates as a clinical-stage privately-held biopharmaceutical company. It focuses on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform. Its platform employs novel oil-in-water nano-droplets for products administered to the skin andnose.The company was founded as a spin-off from the University of Michigan and is headquartered in Ann Arbor, Michigan. | $10M | Series B | Jul 08, 2009 |  |
| BlueWillow Biologics | BlueWillow Biologics operates as a clinical-stage privately-held biopharmaceutical company. It focuses on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform. Its platform employs novel oil-in-water nano-droplets for products administered to the skin andnose.The company was founded as a spin-off from the University of Michigan and is headquartered in Ann Arbor, Michigan. | $12M | Series B | Feb 18, 2009 |  |
| MAP Pharmaceuticals | MAP Pharmaceuticals, Inc., a development stage company, focuses on developing novel inhalation therapies for respiratory and systemic diseases. It has various proprietary product candidates in clinical development, including Unit Dose Budesonide for pediatric asthma in children from six months to eight years of age and MAP0004 for migraine. Thecompany's product portfolio also includes MAP0005 for the treatment of adolescent and adult asthma, and chronic obstructive pulmonary disease; and MAP0001 for the treatment of Type 1 and Type 2 diabetes via pulmonary delivery using its Tempo inhaler. MAP Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Mountain View, California. | $50M | Series D | Mar 28, 2007 |  |
| Serveron | Serveron Corporation develops, delivers, and supports online transformer products, as well as diagnostic services. It offers transformer monitors that provide key asset data, including dissolved gas analysis of the insulating oil of power transformers and other oil-filled equipment; monitoring services, which provide access to transformer monitordata from any Internet-connected Windows personal computer; transformer bushing monitors for power factor testing; transformer advisory service to assist utilities in managing their transformer fleets; and energy asset management to manage remote energy systems through real-time monitoring, control, and reporting. The company’s products and services monitor the operating condition and changes in performance of generation, transmission, and distribution equipment, including power transformers, LTC’s, and bushings. It serves utilities, industrial users, and service organizations in the United States and internationally. The company, formerly known as Micromonitors, Inc., is headquartered in Hillsboro, Oregon. As of January 8, 2008, Serveron Corporation operates as a subsidiary of BPL Global, Ltd. | $5M | Series G | Mar 22, 2007 |  |
| BlueWillow Biologics | BlueWillow Biologics operates as a clinical-stage privately-held biopharmaceutical company. It focuses on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform. Its platform employs novel oil-in-water nano-droplets for products administered to the skin andnose.The company was founded as a spin-off from the University of Michigan and is headquartered in Ann Arbor, Michigan. | $30M | Series A | Oct 21, 2006 |  |
| MAP Pharmaceuticals | MAP Pharmaceuticals, Inc., a development stage company, focuses on developing novel inhalation therapies for respiratory and systemic diseases. It has various proprietary product candidates in clinical development, including Unit Dose Budesonide for pediatric asthma in children from six months to eight years of age and MAP0004 for migraine. Thecompany's product portfolio also includes MAP0005 for the treatment of adolescent and adult asthma, and chronic obstructive pulmonary disease; and MAP0001 for the treatment of Type 1 and Type 2 diabetes via pulmonary delivery using its Tempo inhaler. MAP Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Mountain View, California. | $25.2M | Series C | Jan 31, 2006 |  |

10 of 16 investments shown.

## Co-investors
- Oregon Life Sciences — VC Fund, 5 deals together
- [Ventures West](https://shizune.co/investors/profile/ventures-west) — VC Fund, 5 deals together
- [Nth Power](https://shizune.co/investors/profile/nth-power) — VC Fund, 4 deals together
- El Dorado Investment — VC Fund, 3 deals together
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 2 deals together
- Reference Capital — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Perseus invest in?

Perseus invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series C stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Perseus?

Public channels for Perseus include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Perseus?

The team at Perseus includes Kenneth M. Socha (Senior Managing Director), Alexandra Gardiner (Vice President) and Joanne Marshall Shea (Vice President), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co